EC145 shows anti-tumor activity in ovarian cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

BELGRADE-Endocyte presented phase IIa data from its trial using EC145 (pegylated liposomal doxorubicin) in women with advanced-stage ovarian cancer at the 2009 European Society of Gynaecological Oncology.

BELGRADE-Endocyte presented phase IIa data from its trial using EC145 (pegylated liposomal doxorubicin) in women with advanced-stage ovarian cancer at the 2009 European Society of Gynaecological Oncology. The study participants had a median of four prior exposures to chemotherapy and 88% were diagnosed with having a tumor volume of greater than 5 cm in diameter. The overall disease control rate, defined as stable disease or partial or complete response to therapy, was 40.8% (abstract 1181).

Based on these results, the trial will move into phase IIb, a randomized study of EC145 in combination with doxorubicin HCl (Doxil/Caelyx ) vs doxorubicin HCl alone in women with platinum-resistant ovarian cancer.

Articles in this issue
Should surgery dominate as the standard of care for mesothelioma or be in reserve for a select group of pts?
Early study shows promise for radiofrequency ablation in dysplastic Barrett esophagus
ECCO/ESMO study: Endocrine Rx for prostate cancer carries cardiovascular consequences
Measure for measure: How to make practice benchmarks meaningful
Updated regimens on par with standard therapy in diffuse large B-cell lymphoma
Ultrasound targets lymph node recurrence in breast cancer
Experts contest review article declaring breast MRI causes more harm than good by encouraging radical Rx
JAMA article reignites debate over screening
Moving at the speed of science
International trials: Panitumumab delays disease progression in colon cancer mets
Radiation Rx prevents melanoma’s invasion of lymph nodes
Bone marrow aspiration enhances detection of leukemia cells
FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma
Infection control wins stimulus funds
Women with small HER2+ breast ca face recurrence risk

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian Cancer
Related Content
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Megan Hollasch
March 17th 2025
Article

A phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer

Russ Conroy
March 17th 2025
Article

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.